Latest Interviews
Showing 1–3 of 3 transcripts.
Clear all filters- Milken Institute20 min
A Conversation with First Lady of the United States Jill Biden | Middle East and Africa Summit 2024
Launched in November 2023, President Biden and Dr. Jill Biden initiated the Women's Health Initiative to rectify century-old biases in clinical research by allocating over $1 billion across the NIH, DOD, and ARPA-H for targeted studies on heart disease, endometriosis, and menopause. This federal mobilization aims to eliminate diagnostic delays and economic losses exceeding $2 billion annually, with projections suggesting the initiative could unlock $1 trillion in global economic value by 2040 by reintegration millions of women into the workforce. The program addresses a critical global demand for evidence-based data while challenging misinformation to ensure women experience decades of healthy living rather than the current decade of poor health.
- Milken Institute20 min
A Conversation with FDA Commissioner Robert Califf | Future of Health Summit 2024
Commissioner Califf reflects on his tenure managing the Abbott infant formula recall and reorganizing the FDA Food Program, emphasizing that the agency faces a healthcare delivery crisis rather than an innovation deficit despite the U.S. global leadership in scientific advancement. He advocates for shifting regulatory focus from pre-approval trials to post-market pragmatic studies and new frameworks for AI decision support to address systemic biases and monitor uncontrolled algorithmic drift in clinical environments. Califf concludes by defining essential traits for future leadership, prioritizing executive listening skills and a commitment to high-quality evidence generation while maintaining a strict separation between science-based product decisions and politically influenced policy mandates.
- Goldman Sachs14 min
From “The Way Forward" Conference: Esther Krofah, Executive Director, FasterCures
Faster Cures currently monitors over 200 SARS-CoV-2 therapeutic candidates and 163 vaccine prospects, with the majority of treatments in Phase 2 or 3 testing and key programs like Moderna's mRNA vaccine and the Oxford/AstraZeneca project advancing rapidly. While early data supports Remdesivir and convalescent plasma as partial solutions, experts anticipate effective cures will likely emerge from combination therapies and require Emergency Use Authorizations between fall 2020 and early 2021. Vaccine availability for frontline workers is targeted for late 2020, though the accelerated 12-to-18-month timeline relies on aggressive manufacturing scaling and successful clinical data readouts expected by autumn.